quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 25, 2026

The Federal Reserve's Interest Rate Dilemma Is About to Go From Bad to Warsh -- and the Stock Market May End Up Paying the Price

View original at nasdaq.com
The Federal Reserve's Interest Rate Dilemma Is About to Go From Bad to Warsh -- and the Stock Market May End Up Paying the Price Key Points Jerome Powell's last day as Fed chair is May 15…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Warsh's historically hawkish voting record and desire to reduce the Fed's bloated balance sheet strongly suggest that he would not be in favor of continuing the central bank's existing rate-easing cycle

    60% confidence
  • The Cleveland Fed's Inflation Nowcasting tool forecasts April 2026 TTM inflation at 3.58% as of April 20, 2026

    60% confidence
  • Trump repeatedly urged Powell and members of the FOMC to aggressively cut interest rates to 1% or lower

    60% confidence
  • The stock market began 2026 at its second-priciest valuation over the last 155 years

    60% confidence
  • Major geopolitical events since WWII show markets up a median of 5% six months later; all of them felt really bad at the time

    60% confidence
  • The Iran war resulted in Iran shutting down the Strait of Hormuz to virtually all oil exports; the roughly two-month shipping disturbance represents the largest energy supply disruption in modern history

    60% confidence
  • One of the main reasons investors have supported such an expensive stock market is the belief that the FOMC would further cut interest rates in 2026

    60% confidence
  • If Warsh sells long-term Treasuries and mortgage-backed securities en masse, the expected reaction would be lower bond prices and higher yields — higher lending rates, the exact opposite of what Trump and investors hope for

    60% confidence
  • Kevin Warsh's voting record and commentary point to a hawkish approach; he favored higher interest rates to suppress inflation even as the unemployment rate soared during the Great Recession

    60% confidence
  • If U.S. inflation nears 3.6% in April and continues to trend modestly higher, Warsh may push for higher interest rates, setting him on a public collision course with President Trump and Wall Street

    60% confidence
  • Trump's actions in Iran, coupled with a shift to Kevin Warsh as Fed chair, all but remove the possibility of rate cuts from the equation in 2026

    60% confidence
  • Among geopolitical and major events, those involving oil price shocks have been more likely to trigger steep corrections, bear markets, or even crashes in the Dow, S&P 500, and Nasdaq Composite dating back to 1940

    60% confidence
  • Kevin Warsh has made clear that he believes the Fed should be a passive market participant, which would entail selling a significant portion of the central bank's assets

    60% confidence
  • If Trump wants someone easy on inflation, he got the wrong guy in Kevin Warsh

    60% confidence
  • Stock Advisor's total average return is 967% — a market-crushing outperformance compared to 199% for the S&P 500

    60% confidence
  • While Wall Street and President Trump are both hoping for additional interest rate cuts from a Warsh-led Fed, history suggests this is unlikely

    60% confidence
  • Energy price shocks are rarely short-term events; even if the Iran war resolves relatively soon, the inflationary effects of a two-month or greater crude oil supply disruption will be felt for several quarters

    60% confidence

Data points we hold from this source

Federal Reserve · balance sheet6.7 trillion_USD

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Federal Reserve's Interest Rate Dilemma Is About to Go From Bad to Warsh -- and the Stock Market May End Up Paying the Price — Source | Via News | pt.VIA.NEWS